Tag: GlobeNewswire

Coface delivers a solid net income of €155.5m in an increasingly uncertain environment, including €47.7m in Q3-26; annualised RoATE at 10.7%

Paris, November 2, 2026 – 5.35 p.m.

• Revenue: €1,413.3m, up +1.7% at constant FX and perimeter
  • Credit insurance revenue up +0.9% at constant FX; client activity slightly improved, up +2.5%
  • Client retention remains at a high level (93.1%); pricing remains slightly negative (-1.3%)
  • Non-insurance activities (factoring, Business Information and Debt Collection) growing by +10.0% to €134.9m. Double-digit growth in Business Information continued (+11.2% at constant FX including non-consolidated subsidiaries, and +15.3% with the Cedar Rose acquisition); Debt Collection is up by +28.1% and factoring by +7.3%
• Net loss ratio improved by 1.9 ppt to 37.7%; net combined ratio at 72.4%
  • Gross loss ratio at 36.6%, an improvement of 0.3 ppt over one year with opening year reserving stable and reserve releases still at a high level
  • Net cost ratio up 2.4 ppts at 34.7%, reflecting continued investments in line with Group strategy
• Net income (Group share) of €155.5m, including €47.7m in Q3-26 and annualised RoATE¹ at 10.7%
• John Gaines co-opted to the Board of Directors

Unless otherwise indicated, changes are expressed by comparison with the results as at September 30, 2025

Commenting, Xavier Durand, CEO of Coface, said:

“In the third quarter of 2026, the global economy continued to face significant geopolitical tensions and macroeconomic imbalances.
High energy prices, investments in artificial intelligence and the persistence of high public deficits led to a rise in interest rates, putting the most vulnerable borrowers – both corporates and sovereigns – under pressure. Corporate defaults remained at a record high, resulting in larger claims for credit insurance.
Against this backdrop, Coface reported Q3-26 revenue growth of +5.4%, primarily thanks to a record level of new business production and stronger client activity.
Non-insurance revenue continues to post solid performance with double-digit growth driven by all businesses, including factoring.
Our expertise and vigilance regarding risk management have once again enabled us to keep our combined ratio at a level below our mid-cycle target. We delivered these strong results while continuing to make strategic investments.
As Coface expects corporate defaults to continue their upward trend, we have once again significantly stepped up the number of prevention measures, while remaining committed to our clients.”

Key figures at September 30, 2026

The Board of Directors of COFACE SA examined the consolidated financial statements at September 30, 2026 at its meeting of November 2, 2026. These statements were also previously reviewed by the Audit Committee at its meeting of October 30, 2026.

Income statement items in €m	9M-25	9M-26	Change	% ex. FX*
Insurance revenue	1,128.5	1,135.6	+0.6%	+0.9%
Services revenue	258.0	277.7	+7.6%	+5.3%
REVENUE	1,386.5	1,413.3	+1.9%	+1.7%
UNDERWRITING INCOME (LOSS) AFTER REINSURANCE	222.2	220.2	(0.9)%	(1.7)%
Investment income, net of management expenses, excluding finance costs	45.4	67.0	+47.5%	+44.5%
Insurance Finance Expenses	(0.9)	(39.5)	+4,097.9%	+4,255.4%
CURRENT OPERATING INCOME	266.7	247.8	(7.1)%	(8.8)%
Other operating income / expenses	(5.2)	(5.0)	(3.4)%	+0.4%
OPERATING INCOME	261.6	242.8	(7.2)%	(9.0)%
NET INCOME (GROUP SHARE)	176.3	155.5	(11.8)%	(14.3)%
Key ratios	9M-25	9M-26	Change
Loss ratio after reinsurance	39.6%	37.7%	(1.9)	ppt
Cost ratio after reinsurance	32.3%	34.7%	+2.4	ppts
COMBINED RATIO AFTER REINSURANCE	71.9%	72.4%	+0.5	ppt
Balance sheet items in €m	2025	9M-26	Change
Total equity (Group share)	2,213.0	2,141.1	(3.2)%

* Excluding scope effect

1. Revenue

Coface generated consolidated revenue of €1,413.3m over the first nine months of the year, up +1.7% at constant FX and perimeter, compared with 9M-25. On a reported basis (at current FX and perimeter), revenue was up +1.9%.

Revenue in €m (by activity)	9M-25	9M-26	Change	% ex. FX2
Credit insurance*	1,128.5	1,135.6	+0.6%	+0.9%
Fee and commission income	138.6	142.8	+3.0%	+1.2%
Non-insurance activities	119.4	134.9	+13.0%	+10.0%
Factoring	54.1	57.9	+7.1%	+7.3%
Business Information	54.4	64.8	+19.0%	+9.6%
Debt Collection	10.9	12.2	+11.8%	+28.1%
Total revenue	1,386.5	1,413.3	+1.9%	+1.7%

Insurance revenue (including Bonding and Single Risk) increased by +0.9% at constant FX and perimeter. Commissions were slightly up by 1.2%. A near-record level retention rate (93.1%) had a positive impact on revenue, in a market that remains competitive. New business reached a new record high of €105m, driven by an increase in demand and benefiting from growth investments made by Coface.

Client activity had a positive impact of +2.5% in 9M-26 amid significant political and economic uncertainty, but with a modest pick-up in activity in Europe. Pricing remains negative at -1.3%, a slightly more favorable level than the historical average.

Revenue from non-insurance activities increased by a significant +10.0%, at constant FX and perimeter, compared with 9M-25. Factoring revenue increased by +7.3%, with Germany recording a solid performance (+10.9%) amid strong demand, while Poland is still affected by weak volumes. Business Information revenue pursued its double-digit growth (+11.2% at constant FX including non-consolidated subsidiaries, and +15.3% including the Cedar Rose acquisition). Debt Collection revenue increased from a base that remains modest, by +28.1%.

Revenue in €m (by invoicing region)	9M-25	9M-26	Change	% ex. FX*
Northern Europe	275.4	285.0	+3.5%	+3.5%
Western Europe	287.0	289.3	+0.8%	(0.5)%
Central and Eastern Europe	125.9	126.3	+0.3%	+0.5%
Mediterranean & Africa	410.3	422.6	+3.0%	+2.4%
North America	128.0	125.7	(1.7)%	+0.9%
Latin America	61.5	66.2	+7.6%	+1.5%
Asia-Pacific	98.5	98.1	(0.4)%	+2.7%
Consolidated revenue	1,386.5	1,413.3	+1.9%	+1.7%

In the Northern Europe region, revenue was up +3.5% at constant and current FX. The region recorded strong growth in non-insurance activities due to strong commercial performance in factoring (+10.9%) and Business Information (+18.7%), improved client activity and a sharp increase in new business.

In Western Europe, revenue was down -0.5% at constant FX (+0.8% at current FX and perimeter), backed by solid growth in specialties, but was negatively impacted by the slowdown in client activity against a persistently challenging local backdrop.

In Central and Eastern Europe, revenue was slightly up by +0.5% at constant FX (+0.3% at current FX). Client activity continues to weigh on credit insurance and factoring, particularly in Poland.

In the Mediterranean & Africa region, which is driven by Italy and Spain, revenue increased +2.4% at constant FX and +3.0% at current FX, backed by strong growth in services, the resilience of the Gulf region and the recovery in client activity.

In North America, revenue rose slightly by +0.9% at constant FX (-1.7% on a reported basis). The region is benefiting from improved client activity and a positive sales momentum. The foreign exchange effect remains negative over the period.

In Latin America, revenue was up +1.5% at constant FX and +7.6% at current FX. The slowdown in client activity was offset by the strong increase in new business.

Revenue in the Asia-Pacific region was up by +2.7% at constant FX (-0.4% on a reported basis). The region recorded significant organic growth driven by new business, but revenue was affected by an unfavorable comparison base.

2. Result

• Combined ratio

The combined ratio after reinsurance stood at 72.4% in 9M-26, up 0.5 ppt year on year.

(i) Loss ratio

The loss ratio before reinsurance stood at 36.6%, an improvement of 0.3 ppt year on year. The number of claims was almost stable (-0.9%) compared with the level reached in the third quarter of 2019 while the amount provisioned increased significantly (+10.8%), due to the return of large claims in Q3-26.

The Group’s reserving policy remained unchanged. The amount of provisions related to the opening year, although discounted, remained in line with the historical average. The level of reserve releases is stable at a high level and reflects the rigorous management of past claims. The net loss ratio improved by 1.9 ppt to 37.7% compared with 9M-25.

(ii) Cost ratio

Coface is pursuing its strict cost management policy while keeping up investment, in accordance with the Power the Core strategic plan. In 9M-2026, costs were up +4.6% at constant FX and perimeter and +5.3% at current FX.

The cost ratio before reinsurance stood at 36.8%, up 1.4 ppts year on year. This increase is mainly due to continued investment (2.4 ppts of which 1.4 ppt from service activities). Conversely, the improved product mix (Business Information, Debt Collection and fee and commission income) had a positive effect of 1.0 ppt.

• Financial income

Income from financial investments was +€67.0m in the first nine months of the year. This amount includes a positive FX effect of €4.3m and a negative impact relating to application of IAS 29 (hyperinflation) in Turkey for -€11.0m.

Current income from the portfolio (i.e. excluding gains on sales, impairment and FX) was slightly up, reaching €79.1m. The accounting yield³, excluding gains on sales and fair value effect, was 2.5% in 9M-26. The yield on new investments was 4.0%.

Insurance finance expenses (IFE) amounted to €39.5m in 9M-26. They include a significant FX loss (-€11.7m) on technical liabilities, which reflects the gain recorded on assets and partially on net loss ratio.

• Operating income and net income

Operating income totaled €242.8m in 9M-26, down -7.2%.

The effective tax rate in 9M-26 was 26% (vs. 23% in 9M-25).

Overall, net income (Group share) was €155.5m, down -11.8% compared with 9M-25, including €47.7m in Q3-26.

3. Shareholders’ equity

As of September 30, 2026, Group shareholders’ equity was €2,141.1m, down €71.9m or -3.2% (€2,213.0m at December 31, 2025).

The change is mainly due to positive net income of €155.5m, the dividend payment (-€186m), and the decrease in unrealized capital gains on financial assets (-€71m), as well as FX differences (€9m).

The annualized return on average tangible equity (RoATE) was 10.7% at September 30, 2026, down 0.7 ppt compared with the previous year, mainly due to lower underwriting income.

4. Outlook

The highly fragmented, uneven recovery of shipping through the Strait of Hormuz has not significantly lowered oil prices. At the same time, targeted strikes on Russian refineries have strained the market for petroleum products, particularly diesel. The resulting price increases trickle down throughout the economy and maintain inflationary pressure, leading central banks to raise policy rates.

In parallel, investments in data center capacity continued at a rapid pace. Demand for several components, including memories, far exceeds available supply, thus contributing to inflation. At the end of the quarter, doubts about the financial health of some highly indebted technology players also resurfaced.

The above trends have led to higher borrowing rates which in turn, in a highly indebted economy, reveal the fragility of both corporates and sovereigns (especially France).

Although the Group is based in France, its risk portfolio is highly diversified. France only represents 14% of Coface revenue and 10% of its risk exposure. French government bonds make up approximately 5% of the Group’s investment portfolio.

Against this ongoing difficult backdrop, Coface is staying extremely vigilant and continues to invest in data and technology. Service activities (Business Information, Debt Collection, factoring) grew 10%, including a very good volume of new factoring business. Services growth once again outperformed the insurance business, thus fully justifying Coface’s strategic choices.

Rising interest rates and energy costs will continue to put pressure on the most indebted countries and companies. Consequently, Coface has once again stepped up its targeted preventive measures while maintaining a high acceptance rate to support its clients.

Conference call for financial analysts

Coface’s 9M-2026 results will be discussed with financial analysts during the conference call that will take place on Monday, November 2 at 6.00 p.m. (Paris time). It will be accessible:

• By webcast: Coface 9M-2026 results – webcast
• By conference call (for sell-side analysts): Coface 9M-2026 – conference call

The presentation will be available (in English only) at the following address:

https://www.coface.com/investors/financial-results-and-reports

Appendices

Quarterly results

Income statement items in €m Quarterly figures	Q1-25	Q2-25	Q3-25	Q4-25	Q1-26	Q2-26	Q3-26		%	% ex. FX*
Insurance revenue	382.9	377.1	368.5	370.2	369.8	384.2	381.6		+3.6%	+2.5%
Services revenue	90.3	86.3	81.4	90.6	95.3	89.9	92.5		+13.6%	+8.1%
REVENUE	473.2	463.4	449.9	460.7	465.1	474.2	474.1		+5.4%	+3.6%
UNDERWRITING INCOME (LOSS) AFTER REINSURANCE	85.4	68.2	68.6	60.1	77.6	74.9	67.7		(1.3)%	(4.6)%
Investment income, net of management expenses, excluding finance costs	10.4	15.9	19.1	20.4	22.4	25.3	19.3		+1.1%	+0.1%
Insurance finance expenses	(4.1)	10.8	(7.6)	(8.3)	(15.8)	(13.3)	(10.4)		+35.8%	+39.0%
CURRENT OPERATING INCOME	91.6	95.0	80.1	72.2	84.2	86.9	76.7		(4.3)%	(7.6)%
Other operating income / expenses	(0.4)	(0.3)	(4.5)	(1.3)	(1.4)	(1.0)	(2.6)		(42.3)%	(40.7)%
OPERATING INCOME	91.2	94.7	75.6	70.9	82.8	85.9	74.1		(2.0)%	(5.6)%
NET INCOME (GROUP SHARE)	62.1	62.1	52.1	45.8	53.6	54.2	47.7		(8.4)%	(12.7)%
Income tax rate	23.0%	26.3%	19.9%	24.8%	25.9%	27.9%	24.7%		+ 4.8 ppts

Cumulated results*

Income statement items in €m Cumulated figures	Q1-25	H1-25	9M-25	2025	Q1-26	H1-26	9M-26		%	% ex. FX*
Insurance revenue	382.9	760.0	1,128.5	1,498.7	369.8	754.0	1,135.6		+0.6%	+0.9%
Other revenue	90.3	176.6	258.0	348.6	95.3	185.3	277.7		+7.6%	+5.3%
REVENUE	473.2	936.6	1,386.5	1,847.3	465.1	939.3	1,413.3		+1.9%	+1.7%
UNDERWRITING INCOME (LOSS) AFTER REASSURANCE	85.4	153.6	222.2	282.3	77.6	152.5	220.2		(0.9)%	(1.7)%
Investment income, net of management expenses, excluding finance costs	10.4	26.3	45.4	65.8	22.4	47.7	67.0		+47.5%	+44.5%
Insurance finance expenses	(4.1)	6.7	(0.9)	(9.2)	(15.8)	(29.1)	(39.5)		+4,097.9%	+4,255.4%
CURRENT OPERATING INCOME	91.6	186.6	266.7	338.9	84.2	171.1	247.8		(7.1)%	(8.8)%
Other operating income / expenses	(0.4)	(0.6)	(5.2)	(6.4)	(1.4)	(2.4)	(5.0)		(3.4)%	+0.4%
OPERATING INCOME	91.2	186.0	261.6	332.5	82.8	168.7	242.8		(7.2)%	(9.0)%
NET INCOME (GROUP SHARE)	62.1	124.2	176.3	222.0	53.6	107.8	155.5		(11.8)%	(14.3)%
Income tax rate	23.0%	24.7%	23.3%	23.6%	25.9%	26.9%	26.2%	+2.9 ppts

* Excluding scope effect

CONTACTS

INVESTOR/ANALYST RELATIONS
Thomas Jacquet: +33 1 49 02 12 58 – thomas.jacquet@coface.com
Rina Andriamiadantsoa: +33 1 49 02 15 85 – rina.andriamiadantsoa@coface.com

MEDIA RELATIONS
Saphia Gaouaoui: +33 1 49 02 14 91 – saphia.gaouaoui@coface.com
Adrien Billet: +33 1 49 02 23 63 – adrien.billet@coface.com

FINANCIAL CALENDAR 2026/2027
(subject to change)
2026 Annual results: February 18, 2027, after market close
Q1-2027 results: May 10, 2027, after market close
General Meeting: May 19, 2027
H1-2027 results: August 2, 2027, after market close
9M-2027 results: November 8, 2027, after market close

FINANCIAL INFORMATION
This press release, as well as all of COFACE SA’s regulated information, can be found on the Group’s website: https://www.coface.com/investors

For regulated information on Alternative Performance Indicators (APMs), please refer to our Interim Financial Report for H1-2026 and our 2025 Universal Registration Document (see 3.7 “Key financial performance indicators”)

Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by Wiztrust. You can check the authenticity on the website www.wiztrust.com.

COFACE: FOR TRADE As a global leading player in trade credit risk management for 80 years, Coface helps companies grow and navigate in an uncertain and volatile environment. Whatever their size, location or sector, Coface provides 100,000 clients across some 200 markets. with a full range of solutions: Insurance, Business Information, Debt Collection, Single Risk Insurance, Surety Bonds, Factoring. Every day, Coface leverages its unique expertise and cutting-edge technology to make trade happen, in both domestic and export markets. In 2025, Coface employed 5,511 people and recorded a turnover of ~€1.84 billion. www.coface.com COFACE SA is listed on Compartment A of Euronext Paris ISIN: FR0010667147 / Ticker: COFA

DISCLAIMER – Certain statements in this press release may contain forecasts that notably relate to future events, trends, projects or targets. By nature, these forecasts include identified or unidentified risks and uncertainties, and they may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these statements. Please refer to chapter 5 “Main risk factors and risk management within the Group” of the Coface Group’s 2025 Universal Registration Document filed with the AMF on April 2, 2026 under number D.26-0218 to obtain a description of certain major factors, risks and uncertainties likely to influence the Coface Group’s businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts or to provide new information on future events or any other circumstance.

---

1 RoATE = Return on average tangible equity
2 Excluding scope effect
3 Book yield calculated on the average of the investment portfolio, excluding non-consolidated investments

Attachment

• 2026 11 02 PR COFACE SA – 9M-2026 results

Announcement no. 10/2026
Inside information

Revised financial ambition towards 2030 includes 5-7% organic growth per year and an EBIT margin¹ in constant currencies in the mid-20% range over the period. Return on Invested Capital (ROIC)² is expected to be around 20% in FY 2029/30. For FY 2026/27, Coloplast expects organic revenue growth of 5-7% and an EBIT margin in constant currencies and before special items of around 25%.

Coloplast is updating its financial ambition towards 2030 to reflect changes in the external environment related to the reimbursement change in US biologics, pricing pressure from healthcare reforms and inflationary pressure. Furthermore, the revised guidance includes a step up in investments in innovation and selected commercial areas to drive growth during and beyond the Impact4 period.

The updated financial ambition towards 2030:
Coloplast is committed to accelerating shareholder value creation by delivering organic growth above the market, strong development in EBIT, an improvement in ROIC and strong cash flow generation. The revised financial ambition includes:

• Organic revenue growth of 5-7% per year, from previously organic revenue growth of 7-8% (5-year CAGR until FY 2029/30)
• EBIT margin¹ in constant currencies in the mid-20% range over the period, from previously absolute EBIT growth¹ in line with or above revenue growth over the period (in constant currencies)
• ROIC² is expected to be around 20% in FY 2029/30, from previously more than 20% in FY 2029/30

On organic revenue growth, the revised financial ambition includes the following key assumptions in a market expected to grow 4-5%:

• Mid-single digit growth in Wound & Tissue Repair, from previously around double-digit growth, driven by the 2026 reimbursement change in the out-patient setting in US biologics
• Neutral to negative impact from pricing over the rest of the period
• Based on current estimates, the impact from the Competitive Bidding Program in the US is included
• Unchanged expectations on:
  • Chronic Care: continued good momentum, with growth above the market over the period
  • Interventional Urology: mid- to high-single digit growth over the period
  • A stable macroeconomic environment and no significant changes in tariffs or other trade restrictions
  • A stable supply and distribution of products across the company
  • No significant M&A deals in the period; M&A strategy focused on bolt-on acquisitions

On EBIT margin¹, the revised financial ambition includes the following key assumptions:

• A step up in investments, primarily impacting FY 2026/27, in key strategic priority areas:
  • Innovation and future pipeline beyond Impact4
  • Commercial areas: US Chronic Care, selected markets in Europe and Emerging markets and Interventional Urology
• Biologics margin expected to improve to above 10% in FY 2026/27 and further increase over the Impact4 period
• External headwinds from inflation and pricing pressure from healthcare reforms
• Unchanged expectations on:
  • Gross margin accretion from Biologics and Voice & Respiratory Care and efficiency initiatives in Global Operations, while wage increases in Hungary and ramp up costs will continue to have negative impact
  • Leverage effect in Chronic Care and improvement in profitability in Interventional Urology

‘Funding the journey’ program to support step up in investments and partly offset external headwinds
To support the step up in investments needed for long-term growth and profitability improvements, Coloplast has initiated a broad ‘funding the journey’ program which will free up around DKK 500 million. The aim of the program is to redeploy resources to innovation and areas with significant growth potential, offset some of the external headwinds from inflation on costs of goods sold and headwinds from ramp up costs, and reduce organisational complexity, ultimately supporting our long-term shareholder value creation ambition. The full impact of the program is expected in FY 2027/28, with around 75% impact already in FY 2026/27, primarily impacting operating expenses.

The program includes the following initiatives:

• Rightsizing of our organisation in China to better reflect the current market environment, completed at the end of FY 2025/26 with benefit in FY 2026/27
• Biologics refocusing of the organisation towards in-patient and return to growth in FY 2026/27 to deliver margin improvement
• Simplifying the organisational structure of selected areas
• Addressing indirect procurement spend

Other financial assumptions for the period:

• Net debt/EBITDA ratio is expected to decrease to below 2.0x towards FY 2029/30
• Unchanged dividend policy to pay out excess cash through dividends, with a target payout ratio of 60-80% of net profit
• The remaining assumptions on capex-to-sales ratio, tax rate, NWC-to-sales ratio and free cash flow-to-sales ratio are unchanged

For FY 2026/27, the assumptions are as follows:

• Organic revenue growth of 5-7%:
  • Chronic Care: growth above the market
  • Wound & Tissue Repair: slow start in Biologics in Q1, with return to growth expected in Q2. Advanced Wound Dressings: continued softer momentum in Europe, partly offset by easier baseline in China
  • Interventional Urology: mid- to high-single digit growth
  • Pricing pressure from healthcare reforms in France and Germany
• EBIT margin in constant currencies and before special items of around 25%:
  • Gross margin: inflationary headwinds of 3-4% (impacting raw materials and freight, accounting for around 55% of total costs of goods sold of DKK 9.7 billion in FY 2025/26) and continued ramp-up, primarily in Portugal
  • Step up in investments impacting operating expenses
  • ‘Funding the journey’ to support the step up in investments through resource reallocation, while partly offsetting gross margin headwinds
  • Immaterial impact from tariffs; our products are expected to remain exempted
• Reported revenue growth in DKK of 7-9% (around 2%-points positive impact from currencies), while the reported EBIT margin¹ will include up to 50 basis points positive impact from currencies, calculated using current spot rates
• ROIC² is expected to be around 16%
• Special items expected to be around DKK 200 million, related to our ‘funding the journey’ program
• Capex-to-sales ratio is expected to be around 5%
• The effective tax rate is expected to be around 22%
   

Forward-looking statements
The forward-looking statements in this announcement, including revenue and earnings guidance, do not constitute a guarantee of future results and are subject to risk, uncertainty and assumptions, the consequences of which are difficult to predict.

The forward-looking statements are based on our current expectations, estimates and assumptions and are provided on the basis of information available to us at the present time. Major fluctuations in the exchange rates of key currencies, significant changes in the healthcare sector or major developments in the global economy may impact our ability to achieve the defined long-term targets and meet our guidance. This may impact our company’s financial results.

Contacts

Aleksandra Dimovska
Vice President, Investor Relations
Tel. +45 4911 1800 / +45 4911 2458
Email: dkadim@coloplast.com

Kristine Husted Munk
Senior Director, Investor Relations
Tel. +45 4911 1800 / +45 4911 3266
Email: dkkhu@coloplast.com

Nicklas Overgaard
Senior Manager, Investor Relations
Tel. +45 4911 1800 / +45 4911 3301
Email: dknioha@coloplast.com

Peter Mønster
Head of Media Relations & Corporate Content
Tel. +45 4911 2623
Email: dkpete@coloplast.com

Address
Coloplast A/S
Holtedam 1
DK-3050 Humlebaek
Denmark
Company reg. (CVR) no. 69749917

Website
www.coloplast.com

This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail.

The Coloplast story begins back in 1954. Elise Sørensen is a nurse. Her sister Thora has just had an ostomy operation and is afraid to go out in public, fearing that her stoma might leak. Listening to her sister’s problems, Elise conceives the idea of the world’s first adhesive ostomy bag. Based on Elise’s idea, Aage Louis-Hansen, a civil engineer and plastics manufacturer, and his wife Johanne Louis Hansen, a trained nurse, created the ostomy bag. A bag that does not leak, giving Thora – and thousands of people like her – the chance to live the life they want. A simple solution that makes a difference. Today, the Coloplast Group develops products and services that help millions of people live more independent lives through solutions tailored to their needs. Globally, our business areas include Ostomy Care, Continence Care, Voice & Respiratory Care, Wound & Tissue Repair, and Interventional Urology

The Coloplast logo is a registered trademark of Coloplast A/S. © 2026-11 All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark.

Attachment

• 10_2026_2030_revised_ambition_and_2026_27_financial_guidance

Two Clinical Programs, a 500-Patient Vision, and a November that Could Be a Game-Changer for the Growing Wall Street Story

DENVER, Nov. 02, 2026 (GLOBE NEWSWIRE) —  (247MarketNews.com) — In a market where the latest investment trends often dominate attention, NeOnc Technologies Holdings (NASDAQ: NTHI) is developing a story that could prove far more meaningful.

The clinical-stage biopharmaceutical company is advancing potential treatments for some of the most difficult-to-treat brain cancers while building an ambitious clinical development strategy that could reach approximately 500 patients across 30 hospitals in three countries.

Now, NeOnc is preparing to bring its research into the international spotlight and today the company announced that data from both its intranasal NEO100 and oral NEO212 programs will be presented at the 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO), taking place November 12–15 at the Pennsylvania Convention Center in Philadelphia.

The two poster presentations, scheduled for November 13, represent an important opportunity to showcase the progress of both clinical programs before a specialized audience of neuro-oncology researchers and physicians.

For investors, the timing adds another dimension to an already developing story involving innovative drug delivery, preliminary clinical observations, international development ambitions, and potentially significant market interest.

Two Clinical Programs. One Major Neuro-Oncology Meeting.

NeOnc’s announcement is particularly interesting because it involves two distinct investigational approaches targeting challenging central nervous system cancers.

Presentation Number 1: NEO100 and Updated Clinical Observations is titled: “Durable Radiographic Remission and Prolonged Survival with Intranasal NEO100 in Recurrent WHO Grade III/IV IDH1-Mutant Astrocytoma: Updated Results from a Phase 1/2a Study and Compassionate Use Experience.”

Thomas C. Chen, MD, PhD, of the University of Southern California and NeOnc Technologies Holdings, will present the findings.

The title alone makes this presentation particularly noteworthy. It focuses on updated results involving recurrent WHO Grade III/IV IDH1-mutant astrocytoma, an aggressive category of brain cancer where treatment options remain challenging.

Importantly, the presentation combines information from a Phase 1/2a study and compassionate-use experience.

The emphasis on durable radiographic remission and prolonged survival makes the updated findings worth watching, although the presentation’s title should not be interpreted as proof of established treatment efficacy.

For NeOnc, the presentation offers an opportunity to provide additional scientific context around its intranasal treatment approach and the clinical observations generated to date.

Presentation Number 2: NEO212 and TMZ-Resistant Brain Cancer, “Oral NEO212 in TMZ-Resistant Recurrent GBM and Brain Metastases: Phase 1 Safety, PK, and Early Signals of Activity.”

Josh Neman, PhD, of the University of Southern California and NeOnc Technologies Holdings, will present the research.

This presentation examines NEO212 in the context of recurrent glioblastoma that is resistant to temozolomide (TMZ), as well as brain metastases.

The focus on Phase 1 safety, pharmacokinetics (PK), and early signals of activity is significant because it provides an opportunity to examine how the investigational oral treatment is being evaluated in difficult-to-treat CNS cancers.

NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development.

The two presentations demonstrate that NeOnc is not relying on a single investigational candidate to drive its development strategy.

Instead, the company is advancing two distinct programs that could offer different approaches to addressing the challenges of brain cancer treatment.

NEO100: A Different Approach to Getting Treatment into the Brain

At the center of NeOnc’s development strategy is NEO100, a highly purified form of perillyl alcohol administered intranasally.

The delivery approach is designed to provide a non-invasive route to the brain.

That matters because one of the greatest obstacles in developing treatments for brain cancer is the blood-brain barrier.

The blood-brain barrier serves as the brain’s natural protective defense system, but that protection also creates a major obstacle for drug developers. Many potential therapies struggle to reach tumors in sufficient concentrations because of this biological barrier.

NeOnc is investigating a different approach.

Rather than relying exclusively on conventional delivery methods, its NEO100 program investigates intranasal administration as a potential way to deliver treatment toward the brain, where drug delivery remains one of the biggest obstacles to therapeutic progress.

Early Clinical Observations Give the Story a Foundation

The upcoming SNO presentation follows earlier clinical observations that have attracted attention.

The company’s appearance on Health Uncensored with Dr. Drew on Fox Business Network also brought the patient experience into the conversation.

One patient described reaching two years on therapy and reported tolerating treatment without reactions.

During the discussion, when Dr. Drew asked about the tumor’s status, physician Dr. Wallace responded, “We can’t see it, actually, at this moment.”

It was a striking moment, illustrating why continued research in this field matters. For families facing aggressive brain cancer, the objective isn’t simply another clinical milestone or a better number on a presentation slide.

It is more time together. Another birthday. Another anniversary. Another opportunity to experience everyday life.

The upcoming presentation could provide additional information as the company continues evaluating NEO100.

NEO212: Another Potential Piece of the Brain Cancer Strategy

While NEO100 is attracting attention for its intranasal delivery approach, NEO212 represents another important component of NeOnc’s development strategy.

NEO212 is an investigational oral conjugate of temozolomide and NEO100, which is being studied for central nervous system cancers, including recurrent glioblastoma.

The company’s upcoming SNO presentation will focus on Phase 1 safety, pharmacokinetics, and early signals of activity in TMZ-resistant recurrent glioblastoma and brain metastases.

NEO212 is being developed under an FDA investigational new drug application.

Its completion of Phase 1 dose escalation and progression toward Phase 2 development represent important steps in the company’s broader clinical strategy.

Together, NEO100 and NEO212 give NeOnc two investigational programs to advance, with different administration approaches and areas of clinical investigation.

For investors following the company, the November 13 presentations could provide an important opportunity to learn more about both programs.

A 500-Patient Ambition That Changes the Conversation

The SNO announcement comes against the backdrop of NeOnc’s broader clinical ambitions.

During its appearance on Health Uncensored with Dr. Drew on Fox Business Network, the company outlined plans for a pivotal clinical trial targeting approximately 500 patients across 30 hospitals in three countries.

A proposed trial of that scale is not a small undertaking. It represents a planned expansion of NeOnc’s clinical ambitions and an opportunity to investigate its treatment approach in a much larger patient population.

The proposal also signals where management wants to take the program and the upcoming SNO presentations provide another opportunity to build scientific visibility as NeOnc works toward its longer-term objectives.

More Than Drug Development: A Broader Technology and International Story

NeOnc’s ambitions also extend beyond conventional drug development.

Its research platform combines patented 3D bioprinting technology with artificial intelligence to create patient-derived tumor models and help researchers evaluate potential treatments, which could support a more personalized understanding of tumor biology and treatment response.

The company also highlighted molecular characteristics, including IDH mutations, as part of its precision-medicine strategy.

For the market, the broader takeaway is that NeOnc is building a story around several interconnected capabilities:

• Investigational drug development through NEO100 and NEO212.
• Innovative intranasal and oral delivery approaches.
• Patient-derived tumor modeling.
• AI-assisted research.
• Precision-medicine development.
• International clinical and business ambitions.

The company’s international ambitions have also been reinforced by developments in Abu Dhabi, including the appointment of Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, to the company’s board.

These developments add an international dimension to a company whose clinical ambitions are increasingly extending beyond a single market.

Now Comes the Interesting Part for Traders: Potential Short Squeeze

While the clinical story is compelling on its own, NTHI has another ingredient that could make its shares particularly interesting to traders: short interest.

Based on Nasdaq’s October 15 market-data snapshot, approximately 877,000 shares were reported short.

At the same time, the stock had recovered from an approximate $2.50 low to eclipse the $3 level, where the potential trading implications become interesting.

The reported short position represents approximately 5.6 days of trading volume using the referenced ten-day average. Five or more days to cover is the sweet spot. If short sellers needed to cover 500,000 shares over a relatively short period, that would represent more than three full days of average trading volume.

That is a meaningful amount of potential buying demand relative to the cited trading activity.

The Technical Levels That Could Make a Difference

Based on the recent trading information cited in the original investment analysis, the $3.30–$3.40 area represents an important initial zone to watch.

Above that, the recent high near $3.55 becomes another potential technical hurdle.

A sustained move through that level, particularly if accompanied by expanding trading volume, could attract momentum traders and potentially increase pressure on short positions.

Wall Street’s Price Targets Add Another Layer

Published analyst coverage has also placed considerably higher values on NTHI.

Roth Capital analyst Jonathan Aschoff initiated coverage with a Buy rating and a $20 price target.

The valuation thesis included projected future commercial potential for NEO100 and NEO212, with anticipated launches in 2029 and 2030, respectively, according to the analyst’s model.

Cantech Letter’s summary of the research cited projected 2033 operating income of $667 million.

These figures represent analyst assumptions and projections rather than established financial results or guaranteed future valuations.

Nevertheless, they illustrate the potential commercial opportunity envisioned in the bullish investment thesis if NeOnc’s programs successfully progress through clinical development and ultimately achieve commercialization.

That question could become increasingly relevant as additional milestones arrive.

For a clinical-stage company developing treatments for difficult-to-treat brain cancers, having two investigational programs represented at the same scientific meeting is a meaningful development and it also gives the investment community two distinct areas of research to follow rather than a single clinical catalyst.

The Bigger Picture: Investing in What Matters

There are plenty of companies competing for attention in today’s stock market. Some are selling the promise of faster computers, more powerful chips, or the next generation of artificial intelligence.

NeOnc is pursuing something different and is attempting to advance potential therapies for patients facing one of medicine’s most challenging diseases while developing technology designed to improve how researchers understand tumors and investigate treatment possibilities.

The company’s story now brings together two investigational drug programs, upcoming scientific presentations, a proposed 500-patient international clinical trial, an innovative intranasal delivery strategy, patented research technology, and international relationships.

Add the potential commercial opportunity outlined in analyst research and the trading dynamics associated with previously reported short interest, and NTHI has several developments that investors may want to monitor.

The November 13 SNO presentations could be particularly important because they bring both clinical programs into the scientific spotlight at the same time.

And for patients and families confronting aggressive brain cancers, the ultimate measure of success will be whether promising research can eventually translate into safer and more effective treatment options.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication.  Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

OMAHA, NE, Nov. 02, 2026 (GLOBE NEWSWIRE) — FitLife Brands, Inc. (“FitLife,” or the “Company”) (Nasdaq: FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the third quarter of fiscal 2026 on Monday, November 16, 2026.

In addition, the Company announced that it will hold an investor conference call after market close on November 16, 2026 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 647543.  International participants can dial (973) 528-0163 and provide the same code.

About FitLife Brands
FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers.  FitLife markets over 500 different products online and through various retail locations.  FitLife is headquartered in Omaha, Nebraska.  For more information, please visit our website at www.fitlifebrands.com.

CONTACT: investor@fitlifebrands.com

Please read the announcement in PDF

Attachment

• 2026_26_Share_buyback

In week 44 Kvika banki hf. purchased 14,000,000 of its own shares at the purchase price ISK 189,450,000. See further details below:

Date	Time	No. of shares	Share price	Purchase price
26.10.2026	11:08:30	2,000,000	13.375	26,750,000
27.10.2026	15:22:16	2,000,000	13.6	27,200,000
27.10.2026	15:24:09	2,000,000	13.6	27,200,000
28.10.2026	11:58:19	2,000,000	13.6	27,200,000
28.10.2026	14:05:08	2,000,000	13.55	27,100,000
29.10.2026	15:28:35	4,000,000	13.5	54,000,000
Total		14,000,000		189,450,000

The trade is in accordance with Kvika‘s buyback programme, announced on 11 September 2026, based on the authorisation of the bank’s Annual General Meeting on 18 March 2026.

Kvika has now purchased a total of 82,569,999 shares under the buyback programme, which corresponds to 1.907% of issued shares in the company. The total purchase price is ISK 1,043,799,112. Following these transactions Kvika holds 124,306,459 of own shares which corresponds to 2.871% of issued shares.

Buyback under the programme will be limited to an aggregate purchase price of up to ISK 1,540,550,041 and no more than 165,500,003 shares.

The buyback programme will remain in effect until shares have been repurchased for an aggregate consideration of ISK 1,540,550,041 or 165,500,003 shares have been acquired, whichever occurs first, but no later than 30 April 2027.

The execution of the buy-back programme must comply with Act on Public Limited Companies. No. 2/1995. In addition. the buy-back programme must be implemented as provided for in the Regulation of the European Parliament and of the Council no. 596/2014. on market abuse. as well as the Commission Delegated Regulation (EU) 2016/1052 on regulatory technical standards for the conditions applicable to buy-back programmes and stabilisation measures. which supplements that Regulation.

Further information please contact Kvika‘s investor relations, ir@kvika.is.

SAN ANTONIO, Nov. 02, 2026 (GLOBE NEWSWIRE) — Usio, Inc., (Nasdaq:USIO), a leading provider of integrated, cloud-based electronic payment and embedded financial solutions, today announced plans to release its third quarter of fiscal 2026 financial results after the market closes on Tuesday, November 10, 2026.

Usio’s management will host a conference call on November 10, 2026, at 4:30 p.m. Eastern time to review financial results and provide a business update, followed by a question-and-answer session.

To listen to the conference call, parties within the U.S. should call 1-844-883-3890. International callers should call 1-412-317-9246. All callers should request the Usio conference call. The conference call will also be available via a live webcast, accessible through the company’s website at https://www.usio.com/events/.

A replay of the conference call will be available approximately one hour after the conclusion and will remain accessible through November 25, 2026. The replay may be accessed via the Company’s website or by dialing 1-855-669-9658 (U.S.) or 1-412-317-0088 (International). The replay conference playback code is:
7548744.

To register as a financial professional in order to ask questions during the call, please email ir@usio.com no later than 5:00 p.m. Eastern time on Monday, November 9, 2026.

About Usio, Inc.
Usio, Inc. (Nasdaq: USIO), a leading, cloud-based, integrated FinTech electronic payment solutions provider, offers a wide range of payment solutions to merchants, billers, banks, service bureaus, integrated software vendors and card issuers. The Company operates credit, debit/prepaid, and ACH payment processing platforms to deliver convenient, world-class payment solutions and services to clients through its unique payment facilitation platform as a service. The company, through its Usio Output Solutions division, offers services relating to electronic bill presentment, document composition, document decomposition and printing and mailing services. The strength of the Company lies in its ability to provide tailored solutions for card issuance, payment acceptance, and bill payments as well as its unique technology in the card issuing sector. 

Usio is headquartered in San Antonio, Texas, and has offices in Austin, Texas.

Websites: www.usio.com, www.usioion.com, and www.akimbocard.com. 
Find us on LinkedIn, Facebook® and Twitter.

FORWARD-LOOKING STATEMENTS DISCLAIMER

Except for the historical information contained herein, this release contains forward-looking statements that are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding management’s intentions, beliefs, expectations, and strategies for the future, including statements regarding the Company’s operating and growth strategies. Forward-looking statements can be identified by words such as “believe,” “intend,” “look forward,” “anticipate,” “schedule,” and “expect,” and similar expressions.

These forward-looking statements are subject to risks and uncertainties inherent in the Company’s business that could cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, among others, risk relating to economic conditions, including effects related to the COVID-19 pandemic; the realization of anticipated benefits from the PostCredit acquisition; the Company’s ability to manage growth; the loss of key resellers; relationships with the Automated Clearing House network, bank sponsors, third-party card processing providers, and merchants; the security of the Company’s software, hardware, and information systems; volatility in the Company’s stock price; the need for additional financing; risks associated with new tax legislation; and compliance with complex federal, state, and local laws and regulations, as well as other risks described from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.

One or more of these factors have affected, and in the future, could affect, the Company’s businesses and financial results and could cause actual results to differ materially from management’s plans and projections. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, undue reliance should not be placed on such statements which speak as of the date hereof. The Company undertakes no obligation to update or revise any forward‑looking statements, except as required by law.

Contact:
ir@usio.com
210-249-4055

MCLEAN, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) (the “Company”) today announced the tender results of its previously announced offer to purchase (the “Offer”) any and all of the STACR® (Structured Agency Credit Risk) Notes listed in the table below (the “Notes”). Each of the classes of Notes subject to the Offer were issued by the applicable STACR trust identified in the table below (each, a “Trust”). Freddie Mac is the holder of the owner certificate issued by each Trust and, as a result, the sole beneficial owner of each Trust.

The Company has conducted the Offer in accordance with the conditions set forth in the Offer to Purchase dated October 26, 2026 (the “Offer to Purchase”). Capitalized terms used but not defined in this Press Release have the meanings ascribed to such terms in the Offer to Purchase.

As of 5 p.m., New York City time, on Friday, October 30, 2026 (the “Expiration Time”), approximately $1.1 billion aggregate original principal amount of the Notes had been validly tendered and not properly withdrawn as set forth in the table below:

Title of Security	STACR Trust	CUSIP Number (Rule 144A / Regulation S)	ISIN Number (Rule 144A / Regulation S)	Original Principal Amount		Percentage of Original Principal Amount Tendered and Accepted1	Original Principal Amount Tendered and Accepted
STACR 2020-HQA5 B-1	Freddie Mac STACR REMIC Trust 2020-HQA5	35565TBD0 / U3197KBD0	US35565TBD00 / USU3197KBD01	$225,000,000		100.00%	$225,000,000
STACR 2021-DNA3 B-1	Freddie Mac STACR REMIC Trust 2021-DNA3	35564KFG9 / U3201WFG7	US35564KFG94 / USU3201WFG79	$211,000,000		100.00%	$211,000,000
STACR 2021-DNA5 B-1	Freddie Mac STACR REMIC Trust 2021-DNA5	35564KJA8 / U3201WJA6	US35564KJA88 / USU3201WJA63	$339,000,000		99.95%	$338,820,000
STACR 2021-HQA1 B-1	Freddie Mac STACR REMIC Trust 2021-HQA1	35564KCN7 / U3201WCN5	US35564KCN72 / USU3201WCN57	$223,000,000		95.37%	$212,666,000
STACR 2023-DNA2 M-1B	Freddie Mac STACR REMIC Trust 2023-DNA2	35564KT66 / U3201WT56	US35564KT664 / USU3201WT560	$127,000,000		97.05%	$123,255,000
Total							$1,110,741,000

1. Rounded to the nearest hundredth of a percent.

The Settlement Date for the Notes tendered and accepted for purchase in the Offer is expected to occur on Tuesday, November 3, 2026.

Wells Fargo Securities, LLC and Cantor Fitzgerald & Co. are lead dealer managers, and CastleOak Securities, L.P. is co-dealer manager, for the Offer. For additional information regarding the terms of the Offer, please contact Wells Fargo Securities, LLC at (704) 410-4820 or (866) 309-6316 (toll-free); or Cantor Fitzgerald & Co. at (212) 610-2220. Requests for the Offer to Purchase may be directed to Global Bondholder Services Corporation, as tender agent, at (212) 430-3774 or (855) 654-2015 (toll-free), or by email at contact@gbsc-usa.com.

This announcement does not constitute an invitation to participate in the Offer in or from any jurisdiction in or from which, or to or from any person to or from whom, it is unlawful to make such Offer under applicable securities laws or otherwise. The distribution of materials relating to the Offer, and the transactions contemplated by the Offer, may be restricted by law in certain jurisdictions where it is legal to do so. The Offer is void in all jurisdictions where it is prohibited. If materials relating to the Offer come into your possession, you are required by Freddie Mac to inform yourself of and to observe all of these restrictions. The materials relating to the Offer do not constitute, and may not be used in connection with, an offer or solicitation in any place where offers or solicitations are not permitted by law. If a jurisdiction requires that the Offer be made by a licensed broker or dealer and a dealer manager or any affiliate of a dealer manager is a licensed broker or dealer in that jurisdiction, the Offer shall be deemed to be made by the dealer manager or such affiliate on behalf of Freddie Mac in that jurisdiction.

About Freddie Mac Single-Family Credit Risk Transfer
Freddie Mac’s Single-Family CRT programs transfer credit risk away from U.S. taxpayers to global private capital via securities and (re)insurance policies. We founded the GSE Single-Family CRT market when we issued our first Structured Agency Credit Risk (STACR^®) notes in July 2013. In November 2013, we introduced our Agency Credit Insurance Structure® (ACIS^®) program. Today, CRT serves as the primary source of private capital investment in residential mortgage credit. For specific STACR and ACIS transaction data, please visit Clarity, our CRT data intelligence portal.

About Freddie Mac
Freddie Mac’s mission is to make home possible for families across the nation. We promote liquidity, stability and affordability in the housing market throughout all economic cycles. Since 1970, we have helped tens of millions of families buy, rent or keep their home. Learn More: Website | Consumers | X | LinkedIn | Facebook | Instagram | YouTube

MEDIA CONTACT: Fred Solomon
703-903-3861
Frederick_Solomon@freddiemac.com 

Pursuant to the resolution of the General Meeting of Coop Pank AS (hereinafter Coop Pank) of 8 April 2026 and the resolution of Coop Pank’s Supervisory Board of 9 April 2026, Coop Pank carried out the second stage of its share buyback programme from 2 September to 31 October 2026 (hereinafter the Second Buyback Programme).

The share buybacks were carried out under the authorisation granted by Finantsinspektsioon (the Financial Supervision Authority) on 16 March 2026, permitting Coop Pank to repurchase up to 3,109,716 of its own shares for a maximum total amount of EUR 3,000,000.

Under the Second Buyback Programme, Coop Pank acquired 298,421 shares for a total consideration of EUR 699,300. Throughout the Second Buyback Programme, Coop Pank published summary information on the previous week’s transactions every Monday in a stock exchange announcement.

Comment by Paavo Truu, Chief Financial Officer of Coop Pank:

“The purpose of the Second Buyback Programme was to repurchase our own shares on the market to cover the shares to be issued under the bank’s share option programme. Given the short buyback period and the applicable buyback volume limits, we were unable to repurchase all the shares required to cover the options to be exercised in 2027. The bank will therefore continue repurchasing shares under a third programme until the target volume has been reached. The current authorisation granted by Finantsinspektsioon permits share buybacks until 16 March 2027.”

Coop Pank, based on Estonian capital, is one of the five universal banks operating in Estonia. The bank has 240,600 clients who use everyday banking services. Coop Pank uses the synergy created between retail trade and banking and brings everyday banking solutions closer to people. The majority shareholder of the Bank is a domestic retail chain Coop Eesti, the sales network of which comprises 330 stores.

Additional information:
Paavo Truu
CFO
Phone: 5160 231
E-mail: paavo.truu@cooppank.ee

To Nasdaq Copenhagen A/S 

                                                                                       2 November 2026
                                                                                       Announcement no. 93/2026

Correction: Value dates changed to 4 January 2027 

Jyske Realkredit’s auctions for 1 January 2027 refinancing

Jyske Realkredit plans to carry out the auction from Monday 16^th to Thursday 19^th of November 2026 for loans in cover pool E.

The refinancing amount and bonds to be offered are specified in the table below:

	Open	Close	Alloc.	Name	ISIN	Amount mill.	LCR
Monday 16 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Tuesday 17 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Wednesday 18 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B
Thursday 19 November	09:30	10:00	10:05	1% 321.E.ja.28 IT1	DK0009418832	3600m	1B

Auction terms appear in the appendix.

Questions regarding the bond sale as well as technical matters may be addressed to Jyske Realkredit, Lars Hasløv, Head of Realkredit Treasury tel. (+45) 89 89 92 19 or Christian Bech-Ravn, Director, Head of Investor Relations, tel. (+45) 89 89 92 25.

The information will also be available on Jyske Realkredit’s web site at jyskerealkredit.com.

Yours sincerely,

Jyske Realkredit

Please observe that the Danish version of this announcement prevails.

www.jyskerealkredit.com

Appendix – Auctions terms

Refinancing principles adjustable rate mortgage loans
Jyske Realkredit offers fixed-rate non-callable bonds for adjusting interest rates on the loans.

When adjusting the interest rates, the bonds are sold at one or more auctions. The price is determined as a weighted average of the prices obtained at the auctions.

Type of auction
The auction of bonds in capital centres E will be conducted on Bloomberg’s auction system.

Bids
Bids for the offered bonds must be made in terms of amount and price.

For bonds maturing within 14 months, bids must be made correct to three decimals. For other bonds, bids must be made with an accuracy of two decimals.

For all bonds bids must be made in multiples of DKK 1,000,000

Conditional offer for bonds with interest rate triggers
For the bonds offered with an interest rate trigger, it is a condition for the final completion of the sale (allotment) that there is no increase in interest rates of more than 5 percentage points. Reference is made to the Act on Mortgage Loans and Mortgage Bonds, etc.

Allotment
All bids above the cut-off price will be settled in full at the cut-off fixing spread. For bids at the exact cut-off price, proportional allocation may be used. No bids below the cut-off price will be settled.

All trades concluded will be published through Nasdaq Copenhagen.

Allotment at the auction will take place as soon as possible, and not later than 5 minutes after closing.

Value date
All bonds will be subject to long settlement. The value date of all trades executed at the auction will be 4 of January 2027.

Reverse facility
As the bonds traded will be subject to long settlement, Jyske Realkredit offers a reverse facility to auction participants whose bids have been accepted and who require the bonds after only two days.

By means of the reverse facility, Jyske Realkredit offers to sell the allotted bonds subject to the conventional two settlement days and subsequently repurchase them with 4 of January 2027 as the value date.

The size of the reverse facility will be determined on an individual basis but cannot exceed the amount allotted to each individual bidder.

The reverse facility can be made conditional on the investor providing a corresponding amount of Jyske Realkredit covered bonds (SDO) or mortgage bonds (RO) maturing on 1^st of January 2027 or a corresponding amount of DKK SDO/SDRO level 1B AAA rated covered bonds issued from other Danish mortgage institutions maturing on 1st of January 2027.

Reverse facilities will be arranged on an individual basis by contacting Jyske Realkredit

Credit Ratings
All auctioned bonds issued through Capital Centre E are rated AAA by S&P.

Reservations regarding auctions
If, contrary to expectations, technical problems should prevent Jyske Realkredit from conducting an auction through Bloombergs auction system, a stock ex-change announcement will be issued containing the practical details of the auction.

Other terms
Jyske Realkredit is not obliged to sell the announced offering, and the offering may furthermore be subject to changes following loan disbursements in the auction period. In addition, the entire or parts of the offering may be postponed, but not later than the second-last business day of this quarter.

On or before the second-last business day of this quarter, it must be ascertained whether the number of purchasers was sufficient for all the covered bonds offered. If a sale of bonds has to be cancelled, the market will be notified immediately by a stock exchange announcement.